載入中
NASDAQHealthcareBiotechnology
最新資料
US$7.30
+US$0.02 · +0.27%
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
前收盤價
US$7.30
+US$0.02 · +0.27%
盤中時間採用ET。市場資料可能有所延遲。
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
日內區間
目前US$7.30
52週區間
目前US$7.30
盤中時間採用ET。市場資料可能有所延遲。
Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical firm primarily operating in the clinical development stage. Its overarching mission involves the discovery, acquisition, advancement, and commercialization of novel therapeutic agents and diagnostic tools, all aimed at combating human illnesses and easing patient discomfort. The company boasts a comprehensive pipeline of potential treatments spanning several key medical fields: immunology, rare conditions, infectious diseases, and central nervous system (CNS) disorders. In the realm of immunology, Tonix is progressing with biologics designed to address organ transplant rejection, various autoimmune diseases, and certain forms of cancer. A prominent candidate here is TNX-1500, a humanized monoclonal antibody targeting CD40-ligand, which is being investigated for its utility in preventing both allograft and xenograft rejection, as well as in treating autoimmune disorders. Its rare disease initiatives include TNX-2900, a specific treatment candidate for Prader-Willi syndrome. The infectious disease segment features a diverse array of programs: TNX-801, a vaccine designed to offer protection against smallpox and monkeypox. TNX-1840 and TNX-1850, which are live virus vaccines based on the company's recombinant pox vaccine (RPV) platform, targeting COVID-19. TNX-3500, a small molecule antiviral drug for the treatment of acute COVID-19. TNX-102 SL, a small molecule medication under investigation for Long COVID, a persistent post-acute COVID-19 condition. Finally, the CNS portfolio encompasses both small molecules and biologics intended to manage pain, neurological conditions, psychiatric ailments, and addiction. Notably, TNX-102 SL is also in mid-Phase 3 development for alleviating fibromyalgia symptoms. Other CNS candidates include TNX-1900, which is being developed to prevent migraine headaches, and TNX-1300, a biologic aimed at treating cocaine intoxication. The company was established in 2007 and maintains its headquarters in Chatham, New Jersey.
日內區間
目前US$7.30
52週區間
目前US$7.30
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1310.7萬 USD | 1009.4萬 USD | 776.8萬 USD | — | — |
| 銷貨成本 | 856.5萬 USD | 776.5萬 USD | 474.1萬 USD | — | — |
| 毛利 | 454.2萬 USD | 232.9萬 USD | 302.7萬 USD | — | — |
| 研究與開發 | 4448.6萬 USD | 4044.8萬 USD | 8665.5萬 USD | 8187.6萬 USD | 6883.8萬 USD |
| 銷售、一般及管理費用 | 8575.9萬 USD | 4010.1萬 USD | 3475.2萬 USD | 3021.5萬 USD | 2347.4萬 USD |
| 營業費用 | 1.3億 USD | 1.39億 USD | 1.21億 USD | 1.12億 USD | 9231.2萬 USD |
| 利息收入 | 414.6萬 USD | — | — | 187.3萬 USD | 2.5萬 USD |
| 利息支出 | 8.9萬 USD | — | — | — | — |
| 折舊和攤銷 | 192.5萬 USD | 342.1萬 USD | 429.1萬 USD | 125.3萬 USD | 5萬 USD |
| 營業利益 | −1.26億 USD | −1.37億 USD | −1.18億 USD | −1.12億 USD | −9231.2萬 USD |
| 淨利 | −1.24億 USD | −1.3億 USD | −1.17億 USD | −1.1億 USD | −9228.7萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$27.00
上漲空間 269.86%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年2月5日 | 1:100 | — | — |
股票分割 | 2024年6月10日 | 1:32 | — | — |
股票分割 | 2023年5月10日 | 4:25 | — | — |
股票分割 | 2022年5月17日 | 1:32 | — | — |
股票分割 | 2019年11月1日 | 1:10 | — | — |
股票分割 | 2018年11月28日 | 1:10 | — | — |
已生效 2025年2月5日
1:100
已生效 2024年6月10日
1:32
已生效 2023年5月10日
4:25
已生效 2022年5月17日
1:32
已生效 2019年11月1日
1:10
已生效 2018年11月28日
1:10
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI688.23萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM312.38萬0.00%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF264.25萬0.00%954億 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM146.74萬0.02%64.1億 USD0.28%US$45.46+0.46%
Vanguard Russell 2000 ETFVTWO118.55萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC37.34萬0.03%13.17億 USD0.60%US$183+0.11%
Invesco RAFI US 1500 Small-Mid ETFPRFZ25.89萬0.01%26.7億 USD0.36%US$53.16+0.64%
Vanguard Russell 2000 Value ETFVTWV19.41萬0.01%14億 USD0.06%US$185.81-0.13%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZVanguard Russell 2000 Value ETFVTWVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
